Novartis Slumps, Sandoz Gains, Computacenter Up

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Novartis suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. Novartis shares plunged as much as 10% in early Zurich trading, reducing their gain for the year to about 4%, trailing rival Roche.
- Sandoz nudged up its mid-term guidance and set a goal of increasing the number of biosimilars in its portfolio to more than 100 by 2040, from 13 currently.
- Computacenter shares climb as much as 7.4%, reaching a record high, after the IT services company upgraded its profit before tax guidance for fiscal year 2026 once again, after doing so at its July trading update. The group also reported a revenue beat in the first half, driven by strong AI-related spend in the US.

See omnystudio.com/listener for privacy information.